# Eledon Pharmaceuticals, Inc. (ELDN) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/ELDN
## Company Profile
- Ticker: ELDN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunology
## Stock Data
- Close: 3.75 USD
- Market cap: 272473015.19 USD
- Last updated: 2026-08-11
## Business Overview
### Transplant Immunology Company
Eledon Pharmaceuticals develops therapies intended to protect transplanted organs and cells while reducing reliance on broadly immunosuppressive regimens.
### Tegoprubart
Tegoprubart is an anti-CD40L antibody designed to block a central co-stimulatory pathway involved in transplant rejection while preserving other immune functions.
### Kidney and Islet Transplantation
Clinical programs include kidney transplantation and an investigator-led islet-cell transplant study in people with high-risk type 1 diabetes, where insulin independence has been observed.
### Broader Organ Transplantation
FDA Orphan Drug designation in liver transplantation adds another potential setting for tegoprubart beyond kidney and islet-cell replacement.
## Why The Stock Is Moving

As of Aug 11, 2026, ELDN closed up 1.90% at $3.75. No new same-company headline was identified in the current news window.

## Future Catalysts

- Eledon’s catalysts are tegoprubart and the immunology / transplant pipeline, where the next update can materially move the stock. The company still needs stronger human proof.

## Recent News
- 2026-06-22 11:00 EST — [Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus](https://biopharmsignal.com/news/ELDN/eledon-presents-long-term-extension-phase-2-bestow-results-at-american-transplan-761f9216) — Source: Eledon Pharmaceuticals, Inc.
- 2026-06-08 11:00 EST — [Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine](https://biopharmsignal.com/news/ELDN/eledon-announces-updated-data-from-investigator-initiated-islet-transplant-trial-f9e63a60) — Source: Eledon Pharmaceuticals, Inc.
- 2026-06-04 20:31 EST — [Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions](https://biopharmsignal.com/news/ELDN/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet--7d835714) — Source: Eledon Pharmaceuticals, Inc.
- 2026-05-20 20:05 EST — [Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress](https://biopharmsignal.com/news/ELDN/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-o-fd6070d7) — Source: Eledon Pharmaceuticals, Inc.
- 2026-05-13 20:05 EST — [Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/ELDN/eledon-pharmaceuticals-reports-first-quarter-2026-financial-results-and-recent-b-f0853ca4) — Source: Eledon Pharmaceuticals, Inc.